The credit lines were taken from ING Bank and Alpha Bank.
The funds have not yet been used.
On August 9, the company’s will discuss, in stockholders meeting, a RON8 million multifunctional credit facility from Alpha Bank.
December 31, Antibiotice Iasi had credit facilities of EUR11 million to RBS Bank and of EUR1.5 million to Citi. The company already used EUR9.1 million and EUR1.1 million, respectively, from these facilities.
The company scheduled investments of RON36.6 million in 2012.
Antibiotice is the second-largest nystatin maker in the world, with a 25% market share, according to company information.
Romania’s Health Ministry owns 53% in Antibiotice, while investment fund SIF Oltenia (SIF5.RO) holds a 10% stake.
Thursday, Antibiotice closed flat at RON0.349 a share in Bucharest. (EUR1=RON 4.4635)